How do cells in the body adopt and maintain specialized fates such as that of a brain, heart, or blood cell? From developmental biology, we know that embryonic stem cells (ESCs) gradually progress from a multipotent state, capable of generating all lineages, to a highly specialized state by sequential restriction of their differentiation potential. Indeed, this developmental paradigm can be harnessed in vitro to direct human ESCs into a broad range of specialized cell types in a stepwise manner (Murry and Keller, 2008) . However, in the 1960s John Gurdon and colleagues made the surprising observation that the nucleus of a differentiated frog cell, when transferred into an enucleated egg, could be reprogrammed back to the totipotency of a zygote and then give rise to a whole new frog (Gurdon, 2006) . The potential applications of this nuclear reprogramming strategy became obvious in 1996 with the birth of Dolly the sheep, the first mammal cloned from an adult somatic cell.
Ten years before Dolly, though, pioneering studies by Harold Weintraub and colleagues hinted that more direct routes to lineage specification were possible. They demonstrated that the expression of a single transcription factor, MyoD, is sufficient to convert fibroblast cells and numerous other cell types into skeletal muscle cells, completely bypassing normal developmental lineage progression (Weintraub et al., 1989) . Since then, other remarkable examples of cell-fate reprogramming by a single transcription factor have been reported, including the ectopic induction of eyes on the legs of fruit flies by Pax6 expression, as reported by Walter Gehring (Halder et al., 1995) . However, the usefulness of these approaches for regenerative medicine had remained largely neglected.
This all changed 5 years ago when Takahashi and Yamanaka's landmark study (Takahashi and Yamanaka, 2006) demonstrated that transcription factor-based reprogramming can achieve cellfate transitions comparable in scope to those observed in nuclear transfer studies. Clearly, this induced pluripotent stem cell (iPSC) technology has revolutionized the field of regenerative medicine, triggering thousands of studies aimed at cell therapy, disease modeling, and personalized medicine. However, if the ultimate goal for translational medicine is to produce differentiated cell types on demand, is it indeed necessary to take an iPSC ''detour'' back to pluripotency rather than directly programming a differentiated cell fate as illustrated by the work of Weintraub and Gehring? In 2008, Zhou et al. reported the first example of transcription factor-based reprogramming in regenerative medicine by converting exocrine cells into insulinproducing endocrine cells in the mouse pancreas in vivo. Now three recent studies demonstrate that direct lineage programming can yield a diverse range of medically relevant cell types, such as neurons (Vierbuchen et al., 2010) , cardiomyocytes (Ieda et al., 2010) , and blood cell progenitors (Szabo et al., 2010) . Here we discuss these recent studies in the context of their potential future applications in regenerative medicine and in contrast to the more established iPSC paradigm.
Transcription Factor-Based Reprogramming of Fibroblasts Takahashi and Yamanaka sought to find specific factors that, when expressed in mouse embryonic fibroblasts, could reprogram the somatic cells into pluripotent stem cells (Figure 1 ) (Takahashi and Yamanaka, 2006) . Using retroviral vectors, they expressed 24 candidate genes and selected for reprogrammed cells by incorporating a neomycin resistance and b-galactosidase reporter genes (i.e., bgeo) into Fbx15, a gene expressed in but not essential for pluripotent stem cells. They then used a reductive or ''leave one out'' strategy to determine the minimal set of factors required for reprogramming fibroblasts into iPSCs. Thus, the reprogramming cocktail of Oct4, Sox2, Klf4, and Myc was defined. Since then, many important improvements have been made to this iPSC technology (Hanna et al., 2010) , but, the original work by Takahashi and Yamanaka remains to date the fundamental discovery that inspired the iPSC field. In addition, their findings also prompted researchers to start screening for factor combinations that could direct lineage reprogramming.
In February 2010, Vierbuchen et al. (2010) reported a method for reprogramming fibroblasts into excitatory neurons, called ''iNs'' for induced neurons (Figure 1) . Using a strategy similar to Takahashi and Yamanaka, the authors cloned 19 candidate transcription factors into lentiviruses and then cotransduced the factors into mouse embryonic fibroblasts isolated from a nonneural region of a mouse embryo (E14.5). The cells expressed enhanced green fluorescent protein (EGFP) under control of the Tau locus; Tau is a microtubule-associated protein found most abundantly in the central nervous system and, thus, can be used to selectively identify neurons.
Starting with the 19-factor cocktail, the authors found fluorescent cells that also exhibited molecular hallmarks of neurons (e.g., Tuj1, NeuN, MAP2, Synapsin, vGLUT) 12 days after transduction. The reductive strategy reduced the cocktail to two 3-factor combinations: Ascl1, Brn2, and Mytl1 or Zic1. Extensive electrophysiological studies convincingly demonstrated that the iNs function as typical neurons in vitro.
Nevertheless, the study also left many questions unanswered. For example, although the authors used a doxycycline-inducible system to initiate reprogramming, they did not yet test the stability of the reprogrammed iNs by withdrawing doxycycline. Also, neither transplantations nor a global analysis of molecular properties (e.g., gene expression, chromatin, proteomics) were performed to better characterize iNs' in vivo potential or in vitro identity, respectively. Other critical questions for the field include whether this approach is applicable to human cells and whether modifying transcription factor cocktail will provide access to the myriad of neuronal subtypes of the mammalian nervous system. Six months after Vierbuchen et al.'s report, Ieda et al. (2010) adapted and improved upon the basic strategy to generate induced cardiomyocytes (iCMs). This study used fibroblasts from multiple tissue sources (e.g., cardiac and tail-tip fibroblasts) and included cell-fate mapping data and global gene expression profiles. The study also compared the epigenetic status of the reprogrammed iCMs to primary cardiomyocytes and cardiac fibroblasts (Figure 1 ).
The authors initially tested a reprogramming cocktail of 14 genes encoding transcription factors related to heart development. The fibroblasts for the primary screen were cardiac fibroblast-like cells (not expressing EGFP) isolated from heart explants of transgenic mice expressing EGFP/puromycin under a cardiac-specific alpha myosin heavy chain (aMHC) reporter. Out of the initial pool of 14 factors, Gata4, Mef2c, and Tbx5 (T-box transcription factor) were found to optimally induce the aMHC-GFP reporter (25% of cells) and cardiac Troponin T (8% of cells).
The induced cardiomyocytes were stable for at least 1 week in culture, even when the authors shut off the expression of the three transcription factors. Furthermore, a subset of iCMs exhibited spontaneous contractions and electrical activity in vitro, particularly if the iCMs were derived from cardiac fibroblasts. Next, the authors took the fibroblasts at an early stage of reprogramming and injected them into the heart muscle of live animals. These cells differentiated in situ and formed small isolated cardiomyocyte-like cells that were positive for the myofilament marker a-actinin. However, only small numbers of iCMs were observed in vivo, and it is not known whether these new inhabitants of the heart were electrically coupled to endogenous cardiomyocytes. Finally, lineage-mapping experiments with inducible reporters (i.e., Mesp-Cre/R26R-YFP and Isl1-Cre/R26R-YFP reporter mice) suggested that the fibroblasts were directly reprogrammed to the iCM fate without evidence for an intermediate, mesoderm progenitor stage. Szabo et al. (2010) reported that, unlike the direct reprogramming observed with multitranscription factor cocktails, overexpression of a single factor (Oct4), in combination with exposure to the cytokines SCF (stem cell factor) and FLT3LG (FMS-like tyrosine kinase 3 ligand), reprograms a subset of human dermal fibroblasts into CD45 + /CD34 + hematopoietic progenitor colonies ( Figure 1 ). The resulting cells possess the potential to form both erythroid and myeloid cells when exposed to the appropriate cytokines.
In the three previous studies, the key reprogramming factors were known developmental regulators of the target cell lineage. Thus, it was surprising that OCT4, as a single factor, could drive blood lineage specification. Forced expression of Oct4 in adult mice induced microscopic alterations in their epithelial cells (i.e., epithelial dysplasia), likely because of progenitor cell expansion; however, the authors found no evidence for epithelial transformation into hematopoietic cells or any other ectopic tissue phenotypes (Hochedlinger et al., 2005) . Additionally, Oct4 expression is not required for hematopoietic stem cell maintenance, cell-fate determination, or general hematopoiesis under steady-state conditions or competitive hematopoietic reconstitution (Lengner et al., 2007) . The authors proposed that, despite its lack of expression during normal blood development, OCT4 probably directly binds, and presumably activates, hematopoietic-specific genes in induced blood precursors. Independent of the mechanism, 100 putative hematopoietic colonies were detected from 10,000 fibroblasts 21 days after induction. These colonies were manually picked, and 34% of them were shown to express the pan-hematopoietic marker CD45 when treated with conditions favorable to hematopoietic cells. Additionally, 25% of the cells within this CD45 compartment expressed the blood progenitor marker CD34. In vitro exposure to hematopoietic cytokines stimulated the formation of myeloid and erythroid cells (i.e., myelopoiesis and erythropoiesis), although the authors found no evidence for lymphopoiesis. Lineage specification was not examined at the clonal level, and thus, it is difficult to assess whether the induced hematopoietic progenitors were truly multipotent blood precursors.
When the authors injected the CD45 + cells from Oct4-expressing fibroblasts directly into the femur of mice, they observed low levels (<1%) of human chimerism and CD45 expression in the bone marrow of the mice (NOD/SCID IL2Rg null mice) 10 weeks after injection. The authors interpret these in vivo findings in a positive light, asserting that the induced blood progenitor cells appear to lack leukemic or tumorigenic stem cell properties. However, limited engraftment capabilities and a bias for producing myeloid cells are also common problems observed in hematopoietic precursors derived from human pluripotent stem cells (Murry and Keller, 2008) . In fact, one interpretation of Szabo and colleagues' findings is that Oct4, in a particular context, can partially reprogram fibroblasts toward an unstable near-pluripotent state capable of differentiating along blood lineages in the presence of hematopoietic cytokines. Such a model fits with recent data from Kim et al. (2011) in which neural progenitor cells were induced from mouse fibroblasts that underwent intermediate reprogramming toward pluripotency followed by exposure to cell culture conditions favorable for neural precursor cells.
A Roadmap for Directed Cell-Fate Reprogramming
The various findings on iNs, iCMs, and induced blood progenitors raise the question of whether there is a common roadmap for evaluating current directed reprogramming studies and planning future ones (Box 1). The first question is which exact cell is being reprogrammed? In many cases, fibroblast cultures are isolated from heterogeneous tissues, such as a skin biopsy, heart outgrowth cultures, and neonatal or adult tail-tip cultures.
To define more rigorously the cell of origin of a successful reprogramming event, clonal isolation of the starting cells should represent a standard in future studies. A second step is determining the minimum factors required for reprogramming toward a target cell fate. Most studies to date have used a reductive strategy to whittle down the number of factors required for the minimally sufficient set. This is an important point nicely illustrated by both Ieda et al. and Vierbuchen et al., who (Weintraub et al., 1989) . In the context of human iPSCs, a broad survey of their global molecular state revealed that, despite their pluripotency, these cells may not be identical to human ESCs. Thus, there may exist multiple pluripotent states, and an iPSC may also retain molecular traces of its cell of origin (Ohi et al., 2011) . In the context of regenerative medicine, it remains unclear how close these reprogrammed cells need to be to provide adequate cell types for therapeutic applications without increasing the risk of tumor formation or other aberrant cell behaviors.
A fifth major question is whether all characteristics of the reprogrammed cell are faithfully maintained upon withdrawal of the inducing factors. Experiments that used either DNA excision or nonintegrating gene delivery have demonstrated that, for many passages, iPSCs maintain expression of pluripotent markers, differentiation capacity, and epigenetic state in the absence of reprogramming factors (Hanna et al., 2010) . This stability is likely due to the induction of the intrinsic feedforward network of factors controlling pluripotency (Boyer et al., 2005) . It is still unknown whether similar intrinsic gene expression networks exist for differentiated cell types and whether these networks are triggered during directed reprogramming. Indeed, the answer may vary among different cell types. The complete removal of reprogramming factors, by either excision of the viral genome or the use of nonintegrating strategies (vectors or small molecule), is an important next experiment for addressing these questions in the reprogrammed cell types.
Finally, the most critical question for translational applications is, how well do reprogrammed cells survive, integrate, and respond to physiological cues both in vitro and in vivo? For example, can iNs send and receive synaptic input upon transplantation? Can iCMs efficiently integrate into a damaged heart and truly contribute to its function? Applications of Transcription Factor-Based Reprogramming For translational applications, it is particularly important to consider the advantages and disadvantages of direct reprogramming in comparison to the use of iPSC-derived cell types (Table S1 ). iPSC technology has rapidly become the method of choice for modeling human genetic disease and for subsequent drug-screening efforts (see Minireview by R. Dolmetsch and D.H. Geschwind on page 831 of this issue). iPSCs offer greater scalability and flexibility, and multiple cell types relevant to particular symptoms can be derived from a single iPS cell clone. In addition, rapid progress has been made in using small molecules and protein factors to direct iPSC fate specification, enabling high-efficiency derivation of many lineages following a modular developmental blueprint (Chambers et al., 2009 ). On the other hand, it may be only a matter of time before directed reprogramming can match the cell-type diversity currently accessible only through a pluripotent intermediate. One major weakness of iPSCs, which may be circumvented by direct reprogramming, is the age of the resulting target tissue. When starting with pluripotent cells, current protocols yield differentiated cells that appear to correspond to fetal stages of human development. This is a considerable challenge in the context of modeling late-onset human diseases such as Alzheimer's or Parkinson's diseases (Saha and Jaenisch, 2009) . One intriguing question is whether direct reprogramming will similarly reset developmental timing or whether the age of the fibroblast will impact the age of the target cells obtained. Another potential advantage of direct reprogramming is the overall speed and simplicity of the differentiation conditions. In contrast, disease modeling using iPSCs requires time to generate, expand, characterize, and differentiate pluripotent cells.
The ultimate goal of regenerative medicine is to translate discoveries from the research lab to the clinic, and unfortunately, neither iPSC programming nor direct reprogramming is without pitfalls. Tumor formation remains an important concern for both approaches. Although the transition through an iPSC leads to an additional risk of teratoma formation, both methods carry other challenges, such as incomplete reprogramming, tissueinappropriate differentiation, or insertional mutagenesis caused by the reprogramming factors. Recent gene therapy trials have illustrated that the latter is indeed a serious concern for clinical translation. Directed reprogramming approaches will likely require converting millions of fibroblasts, which greatly increases the risk of an adverse insertional event, whereas clonal iPSC cultures could be either screened for integration into ''safe harbor'' sites (Papapetrou et al., 2011) or established and differentiated without any genetic modification. Finally, one attractive therapeutic strategy that is unique to direct reprogramming is the in situ conversion of cell fate. This approach was pioneered by Zhou et al. in 2008 when they used transcription factors to convert exocrine cells to insulin-producing endocrine lineages in the pancreas of mouse (Zhou et al., 2008) . Thus, the effective in situ conversion of fibroblasts into cardiomyocytes or neurons in patients following heart or brain injury, respectively, seems like science fiction today but may well become an important therapeutic strategy for the future.
Just a few years ago, no good options were available for generating genetically matched tissues for cell therapy or human disease modeling, and researchers were struggling to realize the potential of nuclear transfer-based reprogramming strategies. Today, we have at least two major options, both of which may be generally applicable for future therapeutic studies. Although iPSC technology currently has the upper hand in producing therapeutically relevant cell types, we should not forget that in the context of regenerative medicine, iPSCs had a ''head-start'' of nearly 5 years. Directed reprogramming studies should be able to co-opt the various technical strategies developed for iPSC research in an effort to overcome many of the technical challenges discussed here. Ultimately, the usefulness of directed reprogramming will depend on expanding our basic understanding of the complexity and subtleties required to drive an authentic cell fate across a distant lineage boundary.
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